Insider Selling: Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Sells $8,067,400.00 in Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc N. Casper sold 20,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 24th. The stock was sold at an average price of $403.37, for a total value of $8,067,400.00. Following the completion of the sale, the chief executive officer now directly owns 260,446 shares of the company’s stock, valued at approximately $105,056,103.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Thermo Fisher Scientific stock opened at $410.56 on Friday. The stock’s 50-day simple moving average is $372.71 and its 200-day simple moving average is $334.97. Thermo Fisher Scientific Inc. has a 52 week low of $250.21 and a 52 week high of $420.99. The company has a market capitalization of $161.98 billion, a price-to-earnings ratio of 44.43, a PEG ratio of 1.82 and a beta of 1.04. The company has a quick ratio of 2.02, a current ratio of 2.62 and a debt-to-equity ratio of 0.69.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 22nd. The medical research company reported $3.89 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.22. Thermo Fisher Scientific had a return on equity of 18.18% and a net margin of 14.12%. The business had revenue of $6.92 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the previous year, the business earned $3.04 earnings per share. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 14.95 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.22 dividend. The ex-dividend date of this dividend is Monday, September 14th. This represents a $0.88 annualized dividend and a dividend yield of 0.21%. Thermo Fisher Scientific’s payout ratio is 7.13%.

Several analysts recently commented on TMO shares. Stifel Nicolaus lifted their price objective on Thermo Fisher Scientific from $370.00 to $460.00 and gave the stock a “buy” rating in a report on Thursday, July 23rd. Cleveland Research upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Wednesday, July 15th. UBS Group lifted their target price on Thermo Fisher Scientific from $385.00 to $440.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Citigroup lifted their target price on Thermo Fisher Scientific from $390.00 to $471.00 and gave the company a “buy” rating in a research report on Thursday, July 23rd. Finally, Argus lifted their target price on Thermo Fisher Scientific from $370.00 to $450.00 in a research report on Monday. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $420.50.

Institutional investors have recently made changes to their positions in the company. Quadrant Capital Group LLC lifted its position in shares of Thermo Fisher Scientific by 21.6% in the fourth quarter. Quadrant Capital Group LLC now owns 6,068 shares of the medical research company’s stock worth $1,931,000 after buying an additional 1,078 shares in the last quarter. Equitable Holdings Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth about $423,000. LMR Partners LLP purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth about $314,000. 1832 Asset Management L.P. lifted its position in shares of Thermo Fisher Scientific by 258.8% in the fourth quarter. 1832 Asset Management L.P. now owns 280,902 shares of the medical research company’s stock worth $91,720,000 after buying an additional 202,603 shares in the last quarter. Finally, Brooktree Capital Management purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth about $353,000. Institutional investors and hedge funds own 87.51% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: Gap Down Stocks

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.